Trial Information

Summary: PHI-16: Phase I Trial of 5-Fluoro-2'-deoxycytidine with Tetrahydrouridine

The purpose of this research study is to estimate the highest dose of the investigational anticancer drug 5-fluoro-2'-deoxycytidine (FdCyd) which can safely be given with a fixed dose of the investigational drug tetrahydrouridine (THU). Additional objectives of this study are to describe the side effects of this treatment, to determine the level of FdCyd in blood, and to obtain preliminary information about how tumors with various biochemical characteristics may respond to the drugs.

Patient Inclusion/Exclusion Criteria:

- At least 18 years of age - Diagnosed with advanced neoplastic disease - Patients must have disease which is resistant to standard therapy OR for which no standard therapy exists - Any prior antineoplastic therapy must have been completed at least 4 weeks before study enrollment
- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:50:47 PM